How big is Hyperfine, Inc.?

As of Jun 18, Hyperfine, Inc. has a market capitalization of 54.51 million and reported net sales of 11.73 million with a net profit of -40.30 million over the last four quarters. Shareholder's funds are 49.04 million, and total assets are 58.90 million.

As of Jun 18, Hyperfine, Inc. has a market capitalization of 54.51 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 11.73 million, while the sum of net profit for the same period is -40.30 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 49.04 million, and total assets are reported at 58.90 million.

What does Hyperfine, Inc. do?

Hyperfine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $9 million as of March 2025, with a market cap of $54.51 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -96.28%.

Overview:<BR>Hyperfine, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 54.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: -96.28% <BR>Price to Book: 1.26<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Hyperfine, Inc.?

Is Hyperfine, Inc. overvalued or undervalued?

As of May 11, 2022, Hyperfine, Inc. is considered a risky investment and overvalued due to negative performance metrics, with a Price to Book Value of 1.44 and a concerning EV to Sales ratio of 2.45, while its EV to EBITDA ratio of -0.68 significantly lags behind peers, contributing to a year-to-date decline of 21.17% compared to the S&P 500's 2.44% gain.

As of 11 May 2022, the valuation grade for Hyperfine, Inc. has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company is currently considered overvalued, given its negative performance metrics and ratios. The P/E ratio is not applicable due to losses, while the Price to Book Value stands at 1.44. Additionally, the EV to Sales ratio is 2.45, which is concerning for a company with such poor profitability indicators.<BR><BR>In comparison to its peers, Hyperfine, Inc. shows a significantly worse EV to EBITDA ratio of -0.68, while Semler Scientific, Inc. has a much healthier EV to EBITDA of 23.87. Jin Medical International Ltd. also presents a stark contrast with an EV to EBITDA of -14.24. Hyperfine's return performance has lagged behind the S&P 500, with a year-to-date decline of 21.17% compared to the index's 2.44% gain, reinforcing the notion that the stock is currently overvalued.

Is Hyperfine, Inc. technically bullish or bearish?

As of September 11, 2025, Hyperfine, Inc. is in a mildly bullish trend, supported by a bullish MACD and daily moving average, despite bearish momentum indicated by the weekly RSI, while outperforming the S&P 500 with a year-to-date return of 57.95%.

As of 11 September 2025, the technical trend for Hyperfine, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI indicates bearish momentum, which tempers the overall outlook. The Bollinger Bands show a mildly bullish signal on the weekly and a bullish signal on the monthly, while the KST and OBV both reflect a mildly bullish trend on the monthly. <BR><BR>In terms of performance, Hyperfine has outperformed the S&P 500 across multiple periods, with a year-to-date return of 57.95% compared to the S&P 500's 12.22%, and a one-year return of 44.79% versus 17.14%.